Torrent Pharmaceuticals (TORNTPHARM.BO) Earnings Analysis

Torrent Pharmaceuticals (TORNTPHARM.BO) next reports earnings on 2026-07-30, consensus EPS 14.95 INR. Last quarter (2026-05-22) it missed with EPS 12.8 INR vs 20.19 INR est (-36.6%). It has beaten estimates in 2/8 recent quarters (25%). Trailing P/E 79.31.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does TORNTPHARM.BO next report earnings?

Next earnings date2026-07-30
Consensus EPS estimate14.95 INR
Revenue estimate47.03B

TORNTPHARM.BO earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-2212.8 INR20.19 INR-36.6%Miss
2026-02-1319 INR18.2 INR+4.4%Beat
2025-11-0717.75 INR18.26 INR-2.8%Miss
2025-07-2816.35 INR17.11 INR-4.4%Miss
2025-05-2015.4 INR14.35 INR+7.3%Beat
2025-01-2414.9 INR15.08 INR-1.2%Miss
2024-10-2513.37 INR14.82 INR-9.8%Miss
2024-07-2313.51 INR13.82 INR-2.2%Miss

Beat rate: 2/8 (25%) over reported quarters with consensus data.

TORNTPHARM.BO valuation and analyst view

Trailing P/E79.31
Trailing EPS64 INR
Price / book20.42
Dividend yield0.75%
Market cap1704.33B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is Torrent Pharmaceuticals (TORNTPHARM.BO)'s next earnings date?

Torrent Pharmaceuticals is next scheduled to report on 2026-07-30, with a consensus EPS estimate of 14.95 INR and revenue estimate of 47.03B.

Did TORNTPHARM.BO beat earnings last quarter?

In its 2026-05-22 report, TORNTPHARM.BO posted EPS of 12.8 INR versus a 20.19 INR estimate — a miss of 36.6%.

What is TORNTPHARM.BO's earnings track record?

Over the last 8 reported quarters with consensus data, TORNTPHARM.BO beat estimates 2 times (25%).

What is TORNTPHARM.BO's current P/E ratio and EPS?

TORNTPHARM.BO trades at a trailing P/E of 79.31 on trailing EPS of 64.0003313933017 INR.

What do analysts rate TORNTPHARM.BO?

TORNTPHARM.BO has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.